407 related articles for article (PubMed ID: 22116378)
1. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial.
Meyerbroeker K; Powers MB; van Stegeren A; Emmelkamp PM
Psychother Psychosom; 2012; 81(1):29-37. PubMed ID: 22116378
[TBL] [Abstract][Full Text] [Related]
2. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation.
Powers MB; Smits JA; Otto MW; Sanders C; Emmelkamp PM
J Anxiety Disord; 2009 Apr; 23(3):350-6. PubMed ID: 19223151
[TBL] [Abstract][Full Text] [Related]
3. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
4. Virtual reality versus computer-aided exposure treatments for fear of flying.
Tortella-Feliu M; Botella C; Llabrés J; Bretón-López JM; del Amo AR; Baños RM; Gelabert JM
Behav Modif; 2011 Jan; 35(1):3-30. PubMed ID: 21177516
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of exposure therapy in participants with specific phobia: A randomized controlled trial comparing yohimbine, propranolol and placebo.
Meyerbröker K; Morina N; Emmelkamp PMG
J Anxiety Disord; 2018 Jun; 57():48-56. PubMed ID: 29804894
[TBL] [Abstract][Full Text] [Related]
7. Cognitive behavioral therapy for public-speaking anxiety using virtual reality for exposure.
Anderson PL; Zimand E; Hodges LF; Rothbaum BO
Depress Anxiety; 2005; 22(3):156-8. PubMed ID: 16231290
[TBL] [Abstract][Full Text] [Related]
8. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.
Smits JA; Rosenfield D; Davis ML; Julian K; Handelsman PR; Otto MW; Tuerk P; Shiekh M; Rosenfield B; Hofmann SG; Powers MB
Biol Psychiatry; 2014 Jun; 75(11):840-6. PubMed ID: 24237691
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear.
Guastella AJ; Dadds MR; Lovibond PF; Mitchell P; Richardson R
J Psychiatr Res; 2007 Sep; 41(6):466-71. PubMed ID: 16828803
[TBL] [Abstract][Full Text] [Related]
10. Is virtual reality effective to motivate and raise interest in phobic children toward therapy? A clinical trial study of in vivo with in virtuo versus in vivo only treatment exposure.
St-Jacques J; Bouchard S; Bélanger C
J Clin Psychiatry; 2010 Jul; 71(7):924-31. PubMed ID: 20441721
[TBL] [Abstract][Full Text] [Related]
11. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis.
Parsons TD; Rizzo AA
J Behav Ther Exp Psychiatry; 2008 Sep; 39(3):250-61. PubMed ID: 17720136
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia.
Soravia LM; Heinrichs M; Winzeler L; Fisler M; Schmitt W; Horn H; Dierks T; Strik W; Hofmann SG; de Quervain DJ
Depress Anxiety; 2014 May; 31(5):429-35. PubMed ID: 24265104
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.
Norberg MM; Krystal JH; Tolin DF
Biol Psychiatry; 2008 Jun; 63(12):1118-26. PubMed ID: 18313643
[TBL] [Abstract][Full Text] [Related]
14. Extinction retention predicts improvement in social anxiety symptoms following exposure therapy.
Berry AC; Rosenfield D; Smits JA
Depress Anxiety; 2009; 26(1):22-7. PubMed ID: 18781661
[TBL] [Abstract][Full Text] [Related]
15. Emotional variability and sustained arousal during exposure.
Culver NC; Stoyanova M; Craske MG
J Behav Ther Exp Psychiatry; 2012 Jun; 43(2):787-93. PubMed ID: 22123332
[TBL] [Abstract][Full Text] [Related]
16. Noradrenergic enhancement of associative fear memory in humans.
Soeter M; Kindt M
Neurobiol Learn Mem; 2011 Sep; 96(2):263-71. PubMed ID: 21624479
[TBL] [Abstract][Full Text] [Related]
17. Augmenting treatment efficiency in exposure therapy for PTSD: a randomized double-blind placebo-controlled trial of yohimbine HCl.
Tuerk PW; Wangelin BC; Powers MB; Smits JAJ; Acierno R; Myers US; Orr SP; Foa EB; Hamner MB
Cogn Behav Ther; 2018 Sep; 47(5):351-371. PubMed ID: 29448886
[TBL] [Abstract][Full Text] [Related]
18. Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying.
Rothbaum BO; Anderson P; Zimand E; Hodges L; Lang D; Wilson J
Behav Ther; 2006 Mar; 37(1):80-90. PubMed ID: 16942963
[TBL] [Abstract][Full Text] [Related]
19. Challenges to the traditional exposure paradigm: variability in exposure therapy for contamination fears.
Kircanski K; Mortazavi A; Castriotta N; Baker AS; Mystkowski JL; Yi R; Craske MG
J Behav Ther Exp Psychiatry; 2012 Jun; 43(2):745-51. PubMed ID: 22104655
[TBL] [Abstract][Full Text] [Related]
20. Fear reactivation prior to exposure therapy: does it facilitate the effects of VR exposure in a randomized clinical sample?
Shiban Y; Brütting J; Pauli P; Mühlberger A
J Behav Ther Exp Psychiatry; 2015 Mar; 46():133-40. PubMed ID: 25460259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
